336 related articles for article (PubMed ID: 17072588)
1. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests.
Inoue Y; Terao T; Iwata N; Okamoto K; Kojima H; Okamoto T; Yoshimura R; Nakamura J
Psychopharmacology (Berl); 2007 Feb; 190(2):213-9. PubMed ID: 17072588
[TBL] [Abstract][Full Text] [Related]
2. Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder).
Reed SC; Levin FR; Evans SM
Horm Behav; 2008 Jun; 54(1):185-93. PubMed ID: 18413151
[TBL] [Abstract][Full Text] [Related]
3. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment.
Bixo M; Allard P; Bäckström T; Mjörndal T; Nyberg S; Spigset O; Sundström-Poromaa I
Psychoneuroendocrinology; 2001 Aug; 26(6):551-64. PubMed ID: 11403977
[TBL] [Abstract][Full Text] [Related]
4. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
Steiner M; Ravindran AV; LeMelledo JM; Carter D; Huang JO; Anonychuk AM; Simpson SD
J Clin Psychiatry; 2008 Jun; 69(6):991-8. PubMed ID: 18517289
[TBL] [Abstract][Full Text] [Related]
5. Stress, mood, and cortisol during daily life in women with Premenstrual Dysphoric Disorder (PMDD).
Beddig T; Reinhard I; Kuehner C
Psychoneuroendocrinology; 2019 Nov; 109():104372. PubMed ID: 31357135
[TBL] [Abstract][Full Text] [Related]
6. Heart rate variability in premenstrual dysphoric disorder.
Landén M; Wennerblom B; Tygesen H; Modigh K; Sörvik K; Ysander C; Ekman A; Nissbrandt H; Olsson M; Eriksson E
Psychoneuroendocrinology; 2004 Jul; 29(6):733-40. PubMed ID: 15110922
[TBL] [Abstract][Full Text] [Related]
7. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder.
Girdler SS; Straneva PA; Light KC; Pedersen CA; Morrow AL
Biol Psychiatry; 2001 May; 49(9):788-97. PubMed ID: 11331087
[TBL] [Abstract][Full Text] [Related]
8. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.
Steiner M; Pearlstein T; Cohen LS; Endicott J; Kornstein SG; Roberts C; Roberts DL; Yonkers K
J Womens Health (Larchmt); 2006; 15(1):57-69. PubMed ID: 16417420
[TBL] [Abstract][Full Text] [Related]
9. Treatment of premenstrual dysphoric disorder with the GABA
Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T
Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848
[TBL] [Abstract][Full Text] [Related]
10. Effects of cognitive emotion regulation strategies on mood and cortisol in daily life in women with premenstrual dysphoric disorder.
Nayman S; Beddig T; Reinhard I; Kuehner C
Psychol Med; 2023 Aug; 53(11):5342-5352. PubMed ID: 35979813
[TBL] [Abstract][Full Text] [Related]
11. Negative cognitive styles as risk factors for the occurrence of PMS and PMDD.
Śliwerski A; Bielawska-Batorowicz E
J Reprod Infant Psychol; 2019 Jul; 37(3):322-337. PubMed ID: 30468400
[No Abstract] [Full Text] [Related]
12. Selective serotonin reuptake inhibitors for premenstrual syndrome.
Marjoribanks J; Brown J; O'Brien PM; Wyatt K
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD001396. PubMed ID: 23744611
[TBL] [Abstract][Full Text] [Related]
13. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria.
Jovanovic H; Cerin A; Karlsson P; Lundberg J; Halldin C; Nordström AL
Psychiatry Res; 2006 Dec; 148(2-3):185-93. PubMed ID: 17085022
[TBL] [Abstract][Full Text] [Related]
14. Association between Generalized Anxiety Disorder and Premenstrual Dysphoric Disorder in a Diagnostic Interviewing Study.
Yen JY; Lin PC; Huang MF; Chou WP; Long CY; Ko CH
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32033286
[TBL] [Abstract][Full Text] [Related]
15. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
Halbreich U; Smoller JW
J Clin Psychiatry; 1997 Sep; 58(9):399-402. PubMed ID: 9378691
[TBL] [Abstract][Full Text] [Related]
16. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder.
FitzGerald M; Malone KM; Li S; Harrison WM; McBride PA; Endicott J; Cooper T; Mann JJ
Am J Psychiatry; 1997 Apr; 154(4):556-8. PubMed ID: 9090347
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD.
Jackson C; Pearson B; Girdler S; Johnson J; Hamer RM; Killenberg S; Meltzer-Brody S
Hum Psychopharmacol; 2015 Nov; 30(6):425-34. PubMed ID: 26193781
[TBL] [Abstract][Full Text] [Related]
18. [The premenstrual syndrome].
van der Leij F; Schultz WC; van de Wiel H; van Leeuwen JH
Ned Tijdschr Geneeskd; 2010; 154():A1341. PubMed ID: 20719012
[TBL] [Abstract][Full Text] [Related]
19. The multifactorial aetiology and management of premenstrual dysphoric disorder with leuprorelin acetate.
Dunphy L; Boyle S; Wood F
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38160030
[TBL] [Abstract][Full Text] [Related]
20. Depressive mood and frontal alpha asymmetry during the luteal phase in premenstrual dysphoric disorder.
Lin IM; Tsai YC; Peper E; Yen CF
J Obstet Gynaecol Res; 2013 May; 39(5):998-1006. PubMed ID: 23551544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
